Dipeptidyl Peptidase-4 Inhibitors Associated with Lower Psoriatic Disease Risk in Type 2 Diabetes: A 13-Year Nationwide Cohort Study with Mechanistic Validation.

ABSTRACT: Psoriatic disease, encompassing psoriasis and -psoriatic arthritis, is a chronic inflammatory condition with bidirectional associations with type 2 diabetes mellitus. Current evidence regarding dipeptidyl peptidase-4 inhibitors' effects on psoriatic disease presents conflicting findings, with the impact on psoriatic arthritis remaining unexplored. This study aimed to investigate the association between dipeptidyl peptidase-4 inhibitors use and psoriatic disease risk in diabetic patients. A nationwide population-based cohort study was conducted using Taiwan's National Health Insurance Research Database (2009-2021), including 78,865 patients with type 2 diabetes mellitus: 15,773 dipeptidyl peptidase-4 inhibitors users and 63,092 matched controls. Primary outcomes were incident psoriasis and

SUBMITTER: Hung CT 

PROVIDER: S-EPMC12621422 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature